Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 27, 2023

SELL
$0.68 - $1.11 $6,800 - $11,100
-10,000 Reduced 50.0%
10,000 $7,000
Q4 2022

May 16, 2023

BUY
$0.58 - $1.2 $5,800 - $12,000
10,000 Added 100.0%
20,000 $14,000
Q4 2022

Jan 12, 2023

BUY
$0.58 - $1.2 $11,600 - $24,000
20,000 New
20,000 $14,000
Q2 2022

Jul 26, 2022

SELL
$1.57 - $3.33 $87,097 - $184,735
-55,476 Reduced 26.51%
153,796 $285,000
Q1 2022

Apr 22, 2022

SELL
$2.76 - $4.64 $6,209 - $10,440
-2,250 Reduced 1.06%
209,272 $674,000
Q4 2021

Feb 01, 2022

SELL
$4.09 - $7.16 $136,401 - $238,786
-33,350 Reduced 13.62%
211,522 $910,000
Q2 2021

Jul 29, 2021

BUY
$6.87 - $9.16 $75,570 - $100,760
11,000 Added 4.7%
244,872 $2.06 Million
Q1 2021

Apr 20, 2021

BUY
$7.67 - $13.77 $223,197 - $400,707
29,100 Added 14.21%
233,872 $2.01 Million
Q4 2020

Jan 25, 2021

SELL
$12.07 - $17.95 $287,084 - $426,940
-23,785 Reduced 10.41%
204,772 $2.48 Million
Q3 2020

Oct 23, 2020

BUY
$14.16 - $19.45 $192,958 - $265,045
13,627 Added 6.34%
228,557 $3.71 Million
Q2 2020

Jul 10, 2020

SELL
$6.97 - $17.12 $793,241 - $1.95 Million
-113,808 Reduced 34.62%
214,930 $3.23 Million
Q1 2020

May 14, 2020

BUY
$5.79 - $11.83 $141,304 - $288,711
24,405 Added 8.02%
328,738 $2.39 Million
Q4 2019

Feb 03, 2020

BUY
$3.9 - $6.16 $27,300 - $43,120
7,000 Added 2.35%
304,333 $1.81 Million
Q3 2019

Oct 17, 2019

SELL
$3.01 - $4.49 $28,293 - $42,206
-9,400 Reduced 3.06%
297,333 $1.26 Million
Q2 2019

Aug 20, 2019

SELL
$2.8 - $4.14 $12,880 - $19,044
-4,600 Reduced 1.48%
306,733 $1.19 Million
Q1 2019

Apr 23, 2019

BUY
$2.35 - $4.19 $48,880 - $87,152
20,800 Added 7.16%
311,333 $1.3 Million
Q4 2018

Feb 08, 2019

BUY
$2.17 - $3.8 $630,456 - $1.1 Million
290,533 New
290,533 $630,000

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $129M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track This Portfolio

Track Defender Capital, Llc. Portfolio

Follow Defender Capital, Llc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Defender Capital, Llc., based on Form 13F filings with the SEC.

News

Stay updated on Defender Capital, Llc. with notifications on news.